O-NPAT acts on EGFR, which was found to be overexpressed in nearly 15–20% of ER+ tumors, where clinical trials have also shown the efficacy of adjuvant HER2 modulators along with tamoxifen for ER+ breast tumors (Cleator et al., 2009). This evidence concerns the gene ERBB2 and breast neoplasm.